

NEW

Veterinary handbook

ATREVIA[®] XR

FLURALANER

3 MONTHS

INTRODUCING AN IRRESISTIBLE PROTECTION



EXCLUSIVE FOR DOGS



Ectoparasiticide against
fleas, ticks and mites in
soft chews.

PROTECTION FOR
3 MONTHS



FLEAS



TICKS



MITES

ATREVIA® XR, 3 MONTHS OF IRRESISTIBLE PROTECTION

 FLEAS |  TICKS |  MANGE MITES



FLURALANER FOR QUARTERLY ADMINISTRATION

Fluralaner is a new generation compound belonging to the isoxazoline family. This molecule is rapidly absorbed and distributed, providing greater efficacy compared to phenylpyrazoles (fipronil), neonicotinoids (imidacloprid), pyrethroids (permethrin), macrocyclic lactones (ivermectin), among others.

FLURALANER, PREMIUM ACTIVE INGREDIENT ZERO RESISTANCE

We innovate in the use of fluralaner to give you the freedom to choose the most convenient treatment. Choose between: **ATREVIA® ONE** for 1 month of protection or **ATREVIA® XR** for 3 months.

- NON - RESISTANCE
- FAST ACTION
- DELICIOUS TASTE
- BROAD - SPECTRUM
- MONTHLY OR QUARTERLY DOSAGE
- ENVIRONMENTAL CONTROL

ATREVIA® XR



Weight presentation	Mini 2.5-5 kg	Small 5-10 kg	Medium 10-20 kg	Large 20-40 kg
FLURALANER (mg per tablet)	125 mg	250 mg	500 mg	1000 mg
Tablet Weight	1 g	2 g	4 g	8 g

For dogs weighing more than 40 kg, administer a suitable combination. The tablets are protected by a unitary sealed aluminum blister. It is recommended to dose with food. Atrevia®XR protects for 3 months.

BENEFITS

ATREVIA® XR



ONE OR THREE MONTHS

Choose the most convenient treatment for your patients. Atrevia® One for monthly protection or Atrevia® XR for 3 months of sustained protection against ectoparasites.



FAST AND EFFECTIVE

Atrevia® XR acts from the 90th minute against fleas⁽¹⁾, reaching 99% effectiveness at 8 hours after administration⁽²⁾.



IRRESISTIBLE PROTECTION

Atrevia® XR has high palatability and acceptance. According to field studies, it has a voluntary consumption of 95.64%⁽³⁾.



BROAD SPECTRUM AND ENVIRONMENTAL CONTROL

Atrevia® XR is lethal against fleas, ticks, and mange mites. Its continuous use helps to control immature stages.



HEALTHIER SKIN

Complete recovery in cases of mange, and the perfect complement for the treatment against flea allergy dermatitis (FAD).



SAFETY

Safe in lactating females, puppies from the 8th week and/or 2 kg of weight, dogs with MDR1 GEN mutation and other breeds sensitive to macrocyclic lactones⁽⁷⁾. No serious adverse reactions or neurological reactions have occurred during the studies⁽⁴⁾.



INNOCUITY

The systemic action of Atrevia® XR allows protection without exposing families to insecticides as in topical formulations.



WATER-RESISTANT

Due to its administration route, it can be used the same bath day. Its efficacy is not diminished by the contact of the pet with water.

**ATREVIA® XR IS A NEW GREAT-TASTING SOFT TABLET THAT
ELIMINATES FLEAS, TICKS, AND MITES QUICKLY,
EFFECTIVELY AND SAFELY FOR 3 MONTHS.**






ATREVIA® XR STARTS TO WORK AFTER 90 MINUTES ⁽¹⁾. FIELD STUDIES UNDER REAL CONDITIONS PROVE THEIR EFFECTIVENESS

Fleas Immediate and prolonged action



Atrevia® XR rapidly eliminates fleas within 90 minutes of administration. It is effective against *Ctenocephalides felis* and *Ctenocephalides canis* infestations. It provides environmental control, avoiding reinfestations.




Performance in Fleas
Atrevia® XR exhibits lethal activity for at least 98 days against fleas. This contributes to a better environmental control, maintaining the same activity as the reference product on the market⁽²⁾.

Ticks An enemy with the hours counted



Atrevia® XR has action against adult and immature form of *Rhipicephalus sanguineus*, *Ixodes spp.*, *Dermacentor reticulatus* and *Dermacentor variabilis*. Its use prevents vector-borne diseases, such as ehrlichiosis, babesiosis, anaplasmosis and others. anaplasmosis and others.




Performance in Ticks
Atrevia® XR maintains persistent activity for up to 14 weeks (day 98) against ticks. Studies support the effectiveness of Atrevia® in comparison with other reference products on the market⁽⁵⁾.


Mites An end to mange



Atrevia® XR is great for the control of dermatological problems caused by *Demodex canis*, *Sarcoptes scabiei var. canis* and *Otodectes cynotis*. Our field studies support its effectiveness in controlling the associated clinical signs: plaques, scales, crusts, comedones, papules, pustules, alopecia and erythema.



Demodectic mange
A single dose of Atrevia® XR allowed the resolution of 100% of demodicosis cases from day 42, after administration ⁽⁶⁾.



Sarcoptic mange
Atrevia® XR achieved 90 % effectiveness on day 98 after administration. Most cases of scabies can be resolved with a single dose⁽⁶⁾.

PROTECTION PROVEN
BY FIELD STUDIES UNDER
REAL-LIFE CONDITIONS

ATREVIA® XR

HIGH PALATABILITY

Atrevia® has a high palatability and acceptance. According to field studies, it has a voluntary consumption of 98 %⁽³⁾.

Score	Quantity	Percentage
0	8	1.11%
1	7	0.97%
2	12	1.67%
3	693	96.25%



Score: **0** Animal should be forced to eat the tablet **1** Animal shows interest initially, but should be forced to eat the tablet **2** Animal shows interest and eats the tablet when it is placed on its snout **3** Animal smells the tablet and eats it voluntarily

QUICK ACTION ONSET

Atrevia® XR starts to eliminate fleas from the 90th minute ⁽¹⁾ after administration. The table describes the progression during the first 4 action hours of the product. The baseline count is given for reference.

	Baseline Count	90´	120´	180´	240´
Mean (Average)	185 (179)	0.83(1)	9.83(9.5)	30(29.5)	84(89.5)
Count Range	95-261	0-2	2-19	19-42	38-114
Effectiveness		0.45%	5.32%	16.22%	45.41%


Start of activity
Average: 91´
Range: 88´- 98´

PROVEN SAFETY

No serious adverse reactions were reported during testing of Atrevia® XR⁽⁴⁾.

Observed Reactions						
Vomiting	Loss of appetite	Diarrhea	Lethargy	Polydipsia	Flatulence	Total
2	0	1	1	1	0	5
0.00%	0.00%	0.27%	0.27%	0.27%	0.00%	1.36%

LEARN MORE ABOUT
OUR SUPERCHEWS™



Exclusive technology developed by Agrovet Market for the production of chewable tablets. Learn more about the benefits of SUPERCHEWS™.

SOFT CONSISTENCY


Softer consistency compared to other products.

ATTRACTIVE SMELL AND TASTE

Exclusive blend of flavorings, which masks the taste of the active ingredients.

HIGH ACCEPTANCE

Studies support its high acceptance with a voluntary consumption of 98% in treated dogs.



TOTAL DISINTEGRATION

Proprietary association of two synergistic disintegrants, facilitates disintegration of the tablets.

CONVENIENCE

Easy administration in dogs with oral problems or reluctant to take medication.

DIVERSITY

Tablets in different sizes according to weight range.



ATREVIA® XR

Available in 1 unit box and 4 units box.


BIBLIOGRAPHIC REFERENCES

1. Chávez L. 2021. Evaluation of the onset time of flea-killing activity of a quarterly fluralaner-based oral formulation in canines. 2. Chávez L., Liao V. 2021. Evaluation of the effectiveness, tolerance, and residual effects of two fluralaner-based oral formulations for the treatment and control of fleas in naturally infested canines. 3. Chávez L., Liao V. 2021. Evaluation of the palatability of a quarterly fluralaner-based chewable tablet in canines. 4. Chávez L., Liao V. 2021. Evaluation of the safety of a quarterly fluralaner-based oral formulation in canines. 5.- Chávez L., Liao V. 2021. Evaluation of the effectiveness, tolerance, and residual effects of two fluralaner-based oral formulations for the treatment and control of ticks in naturally infested canines. 6.- Chávez L., Liao V. 2021. Evaluation of the effectiveness, tolerance, and residual effects of two fluralaner-based oral formulations for the treatment and control of mites and the reduction of their clinical signs in canines. 7.- External references.

NEW

ATREVIA®

FLURALANER



INTRODUCING AN IRRRESISTIBLE PROTECTION



Recommend ATREVIA® XR now.

The new chewable tablet with an irresistible taste for three months of protection. The care that every doglover seeks for their pet.

+51 (1) 922 926 786

sales@agrovvetmarket.com

fluralaner.vet

Facebook/atrevia Instagram/atreviadogs



Sample materials, packaging, whether digital or printed, are provided by Agrovvet Market or its representatives for informational purposes only. The content is global and general in nature and shall not, under any circumstances, be construed as an attempt to undermine, infringe, or challenge the validity of any registration, patent, or intellectual property right in the country where this information is distributed or received.

For more information about Atrevia® and its distribution network, go to: petmedica.vet

Av. Canadá 3798 - San Luis 15021. Lima - Perú

☎ 511 2 300 300

ATREVIA® IS A PRODUCT OF PETMEDICA®, THE COMPANION ANIMAL DIVISION OF AGROVET MARKET S.A.

petmedica®
Strengthening Bonds